drugset

drugset / Trial / NCT00209352

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

NCT00209352 ↗

Phase 3 Completed 120 enrolled Fred Hutchinson Cancer Center Burroughs Wellcome · collab National Institutes of Health (NIH) · collab

RandomizedParallel-groupDouble-blind

Summary

The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.

Timeline

Start: 1985-06
Primary completion: —
Completion: 2004-07

Publications

Results Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. Blood. 2006 Mar 1;107(5):1800-5. doi: 10.1182/blood-2005-09-3624. Epub 2005 Nov 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acyclovir	Small molecule	800 mg	Oral

Indications